by TractManager | Apr 22, 2022 | Molecular Test Assessment
This report evaluates the analytical validity, clinical validity, and clinical utility of the PrismRA test. According to the laboratory, the PrismRA molecular signature test identifies which patients with rheumatoid arthritis (RA) are unlikely to respond to tumor...
by TractManager | Apr 22, 2022 | Health Technology Assessment
Focus of the Report: The focus of this Health Technology Assessment is the use of phrenic nerve stimulation (PNS) with the remedē System for the treatment of central sleep apnea (CSA).Technology Description: Phrenic nerve stimulation (PNS), also known as diaphragm...
by TractManager | Apr 22, 2022 | Emerging Technology Report
The Agili-C is an aragonite scaffold implant indicated for the treatment of an International Cartilage Repair Society grade III or above knee-joint surface lesion(s), with a total treatable area of 1-7cm2, without severe osteoarthritis (Kellgren-Lawrence grade 0-3).If...
by TractManager | Apr 21, 2022 | Precision Medicine Insights
This report reviews the use of preimplantation genetic testing for polygenic disorders (PGT-P) using polygenic risk scores for the purpose of embryo selection.If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Apr 21, 2022 | News
The U.S. Food and Drug Administration (FDA) is warning patients and healthcare providers about the risks of false results with genetic noninvasive prenatal screening tests.Noninvasive prenatal screening (NIPS) tests analyze small fragments of fetal DNA, called...
Recent Comments